Development of a cell-based bioassay for phospholipase A2-triggered liposomal drug release

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Arouri, Ahmad ^a   Trojnar, Jakub ^a   Schmidt, Steffen ^a   Hansen, Anders H ^a   Mollenhauer, Jan ^a   Mouritsen, Ole G ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHATIDYLCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHATIDYLGLYCEROL; CHOLESTEROL; LIPOSOME; LUCIFERIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; 1,2-DISTEAROYLLECITHIN; DISTEAROYL PHOSPHATIDYLGLYCEROL; DRUG CARRIER;

ARTICLE; BIOASSAY; BIOLUMINESCENCE; CELL BASED BIOASSAY; CELL ENGINEERING; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG FORMULATION; DRUG RELEASE; LIPOSOMAL DELIVERY; PEGYLATION; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; CHEMISTRY; HUMAN; LUMINESCENCE; MCF-7 CELL LINE; MEDICINAL CHEMISTRY; METABOLISM; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

BIOLOGICAL ASSAY; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; DRUG CARRIERS; DRUG LIBERATION; HUMANS; LIPOSOMES; LUMINESCENT MEASUREMENTS; MCF-7 CELLS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; PHOSPHOLIPASES A2;

EID: 84929180270     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125508     Document Type: Article

References (49)

1. Gregoriadis G, Swain CP, Wills EJ, Tavill AS. Drug-carrier potential of liposomes in cancer chemotherapy. The Lancet. 1974; 202: 1313-1316.
2. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: Lessons learned. J Controlled Release. 2012; 160: 117-134. doi: 10.1016/j.jconrel.2012.03.020 PMID: 22484195
3. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012; 7: 49-60. doi: 10.2147/IJN.S26766 PMID: 22275822
4. Park K. Targeted vs. non-targeted delivery systems: reduced toxicity over efficacy. J Controlled Release. 2014; 178: 126. doi: 10.1016/j.jconrel.2014.02.018 PMID: 24606869
5. Arouri A, Hansen AH, Rasmussen TE, Mouritsen OG. Lipases, liposomes and lipid-prodrugs. Curr Opin Colloid Interface Sci. 2013; 18: 419-431.
6. Mouritsen OG, Andresen TL, Halperin A, Hansen PL, Jakobsen AF, Jensen UB, et al. Activation of interfacial enzymes at membrane surfaces. J Phys: Condens Matter. 2006; 18: S1293-S1304. doi: 10.1088/0953-8984/18/28/S12 PMID: 21690842
7. Six DA, Dennis EA. The expanding superfamily of phospholipase A2 enzymes: classification and characterization. Biochim Biophys Acta. 2000; 1488: 1-19. PMID: 11080672
8. Murata K, Egami H, Kiyohara H, Oshima S, Kurizaki T, Ogawa M. Expression of group-II phospholipase A2 in malignant and non-malignant human gastric mucosa. Br J Cancer. 1993; 68: 103-111. PMID: 8318399
9. Belinsky GS, Rajan TV, Saria EA, Giardina C, Rosenberg DW. Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth. Mol Carcinog. 2007; 46: 106-116. PMID: 17091473
10. Tribler L, Jensen LT, Jørgensen K, Brünner N, Gelb MH, Nielsen HJ, et al. Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue. Anticancer Res. 2007; 27: 3179-3185. PMID: 17970059
11. Hu J-j, Tian G, Zhang N. Cytosolic phospholipase A2 and its role in cancer. Clin Oncol Cancer Res. 2011; 8: 71-76.
12. Cai Q, Zhao Z, Antalis C, Yan L, Del Priore G, Hamed AH, et al. Elevated and secreted phospholipase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB J. 2012; 26: 3306-3320. doi: 10.1096/fj.12-207597 PMID: 22767227
13. Scott KF, Sajinovic M, Hein J, Nixdorf S, Galettis P, Liauw W, et al. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie. 2010; 92: 601-610. doi: 10.1016/j.biochi.2010.03.019 PMID: 20362028
14. Abe T, Sakamoto K, Kamohara H, Hirano Y, Kuwahara N, Ogawa M. Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int J Cancer. 1997; 74: 245-250. PMID: 9221799
15. Yamashita S, Yamashita J, Ogawa M. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer. 1994; 69: 1166-1170. PMID: 8198986
16. Moghimi SM, Farhangrazi ZS. Just so stories: The random acts of anti-cancer nanomedicine performance. Nanomed. 2014; 10: 1661-1666.
17. Andresen TL, Jensen SS, Jørgensen K. Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog Lipid Res. 2005; 44: 68-97. PMID: 15748655
18. de Jonge MJA, Slingerland M, Loos WJ, Wiemer EAC, Burger H, Mathijssen RHJ, et al. Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur J Cancer. 2010; 46: 3016-3021. doi: 10.1016/j.ejca.2010.07.015 PMID: 20801016
19. Pedersen PJ, Christensen MS, Ruysschaert T, Linderoth L, Andresen TL, Melander F, et al. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs. J Med Chem. 2009; 52: 3408-3415. doi: 10.1021/jm900091h PMID: 19402667
20. Pedersen PJ, Adolph SK, Subramanian AK, Arouri A, Andresen TL, Mouritsen OG, et al. Liposomal formulation of retinoids designed for enzyme triggered release. J Med Chem. 2010; 53: 3782-3792. doi: 10.1021/jm100190c PMID: 20405849
21. Arouri A, Mouritsen OG. Anticancer double lipid prodrugs: liposomal preparation and characterization. J Liposome Res. 2011; 21: 296-305. doi: 10.3109/08982104.2011.563365 PMID: 21438721
22. Arouri A, Mouritsen OG. Phospholipase A2-susceptible liposomes of anticancer double lipid-prodrugs. Eur J Pharm Sci. 2012; 45: 408-420. doi: 10.1016/j.ejps.2011.09.013 PMID: 21946258
23. Arouri A, Mouritsen OG. Membrane-perturbing effect of fatty acids and lysolipids. Prog Lipid Res. 2013; 52: 130-140. doi: 10.1016/j.plipres.2012.09.002 PMID: 23117036
24. Viviani VR. The origin, diversity, and structure function relationships of insect luciferases. Cell Mol Life Sci. 2002; 59: 1833-1850. PMID: 12530517
25. Rousseau J, Escriou V, Perrot P, Picarda G, Charrier C, Scherman D, et al. Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther. 2010; 17: 387-397. doi: 10.1038/cgt.2009.89 PMID: 20075983
26. Navizet I, Liu Y, Ferré N, Sanjuán DR, Lindh R. The chemistry of bioluminescence: An analysis of chemical functionalities. ChemPhysChem. 2011; 12: 3064-3076. doi: 10.1002/cphc.201100504 PMID: 21997887
27. Kheirolomoom A, Kruse DE, Qin S, Watson KE, Lai C- Y, Young LJT, et al. Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Controlled Release. 2010; 141: 128-136. doi: 10.1016/j.jconrel.2009.08.029 PMID: 19748536
28. Fraga H. Firefly luminescence: A historical perspective and recent developments. Photochem Photobiol Sci. 2008; 7: 146-158. doi: 10.1039/b719181b PMID: 18264582
29. Marques SM, Esteves da Silva JCG. Firefly bioluminescence: A mechanistic approach of luciferase catalyzed reactions. IUBMB Life. 2009; 61: 6-17. doi: 10.1002/iub.134 PMID: 18949818
30. Ignowski JM, Schaffer DV. Kinetic analysis and modeling of firefly luciferase as a quantitative reporter gene in live mammalian cells. Biotechnol Bioeng. 2004; 86: 827-834. PMID: 15162459
31. Hiyama M, Akiyama H, Yamada K, Koga N. Theoretical study of firefly luciferin pKa values-relative absorption intensity in aqueous solutions. Photochem Photobiol. 2013; 89: 571-578. doi: 10.1111/php.12052 PMID: 23360188
32. Dabholkar RD, Sawant RM, Mongayt DA, Devarajan PV, Torchilin VP. Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm. 2006; 315: 148-157. PMID: 16616818
33. Morton RA, Hopkins TA, Seliger HH. The spectroscopic properties of firefly luciferin and related compounds. An approach to product emission. Biochemistry. 1969; 8: 1598-1607. PMID: 5805299
34. Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959; 234: 466-468. PMID: 13641241
35. Jensen SS, Andresen TL, Davidsen J, Høyrup P, Shnyder SD, Bibby MC, et al. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther. 2004; 3: 1451-1458. PMID: 15542784
36. McElroy WD. Properties of the reaction utilizing adenosinetriphosphate for bioluminescence. J Biol Chem. 1951; 191: 547-557. PMID: 14861201
37. Pinto da Silva L, Esteves da Silva JCG. Kinetics of inhibition of firefly luciferase by dehydroluciferyl-coenzyme A, dehydroluciferin and L-luciferin. Photochem Photobiol Sci. 2011; 10: 1039-1045. doi: 10.1039/c0pp00379d PMID: 21409209
38. Ribeiro C, Esteves da Silva JCG. Kinetics of inhibition of firefly luciferase by oxyluciferin and dehydroluciferyl-adenylate. Photochem Photobiol Sci. 2008; 7: 1085-1090. doi: 10.1039/b809935a PMID: 18754056
39. Cooper S. Distinguishing between linear and exponential cell growth during the division cycle: Singlecell studies, cell-culture studies, and the object of cell-cycle research. Theor Biol Med Model. 2006; 3: 10. PMID: 16504098
40. Leidy C, Linderoth L, Andresen TL, Mouritsen OG, Jørgensen K, Peters GH. Domain-induced activation of human phospholipase A2 type IIA: Local versus global lipid composition. Biophys J. 2006; 90: 3165-3175. PMID: 16461407
41. Zhu G, Mock JN, Aljuffali I, Cummings BS, Arnold RD. Secretory phospholipase A2 responsive liposomes. J Pharm Sci. 2011; 100: 3146-3159. doi: 10.1002/jps.22530 PMID: 21455978
42. Kraske WV, Mountcastle DB. Effects of cholesterol and temperature on the permeability of dimyristoylphosphatidylcholine bilayers near the chain melting phase transition. Biochim Biophys Acta. 2001; 1514: 159-164. PMID: 11557016
43. Mayer LD, Krishna R, Webb M, Bally M. Designing liposomal anticancer drug formulations for specific therapeutic applications. J Liposome Res. 2000; 10: 99-115.
44. Hansen AH. Development of liposome-based platforms for anticancer drug delivery. MSc thesis. 2013. Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense.
45. Arechabala B, Coiffard C, Rivalland P, Coiffard LJM, Roeck-Holtzhauer YD. Comparison of cytotoxicity of various surfactants tested on normal human fibroblast cultures using the neutral red test, MTT assay and LDH release. J Appl Toxicol. 1999; 19: 163-165. PMID: 10362266
46. Davidsen J, Vermehren C, Frokjaer S, Mouritsen OG, Jørgensen K. Drug delivery by phospholipase A2 degradable liposomes. Int J Pharm. 2001; 214: 67-69. PMID: 11282239
47. Jørgensen K, Vermehren C, Mouritsen OG. Enhancement of phospholipase A2 catalyzed degradation of polymer grafted PEG-liposomes: effects of lipopolymer-concentration and chain-length. Pharm Res. 1999; 16: 1491-1493. PMID: 10496671
48. Davidsen J, Mouritsen OG, Jørgensen K. Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes. Biochim Biophys Acta. 2002; 1564: 256-262. PMID: 12101020
49. Rosholm KR, Arouri A, Hansen PL, González-Párez A, Mouritsen OG. Characterization of fluorinated catansomes: A promising vector in drug-delivery. Langmuir. 2012; 28: 2773-2781. doi: 10.1021/la2039834 PMID: 22149538